Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APJ agonist nanobody
- Development stage
- Preclinical
- Lead developer
- BioAge Labs
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
The APJ agonist nanobody is a single-domain antibody (nanobody) biologic developed by JiKang Therapeutics and BioAge Labs. It targets the apelin receptor (APJ), a G protein-coupled receptor involved in metabolic regulation, cardiovascular function, and muscle maintenance. The nanobody is designed to be a long-acting injectable and is significantly more potent than the natural ligand apelin, with an EC50 comparable to best-in-class small molecule agonists. It is currently being advanced toward IND-enabling studies for the treatment of obesity and other metabolic diseases, with an Investigational New Drug (IND) filing expected in 2026.
- Other names
- Apelin receptor agonist nanobodyAPJ nanobody
02
Targets
APLNR (Apelin receptor)
Beyond the preview
Go deeper on APJ agonist nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APJ agonist nanobody.